RPHM
Reneo Pharmaceuticals, Inc. [RPHM] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RPHM Stock Summary
In the News
RPHM Financial details
Company Rating
-
Market Cap
57.63M
Income
-65.46M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
55
Optionable
No
Shortable
Yes
Earnings
25 Mar 2024
P/E
-0.87
Forward P/E
-
PEG
-1.73
P/S
-
P/B
0.5
P/C
-
P/FCF
-0.94
Quick Ratio
9.26
Current Ratio
9.49
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.3
EPS next Y
-
EPS next Q
-
EPS this Y
-6.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-12.31%
-
-
-
-
SMA20
12.8%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-60%
ROC
-0.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.98-11.295
52W High
-
52W Low
-
RSI
70.12
Rel Volume
1.76
Avg Volume
247.9K
Volume
437.52K
Perf Week
18.95%
Perf Month
18.95%
Perf Quarter
-
Perf Half Y
13.75%
-
-
-
-
Beta
0.241
-
-
Volatility
0.61%, 1.24%
Prev Close
5.2%
Price
18.2
Change
8.33%
Company Profile
- Volume Average 247.9K
- Market Capitalization 57.63M
- Employee 55
- CEO Mr. Gregory J. Flesher
- Headquarters Irvine,CA,US
- IPO Date 2021-04-08
-
Website
https://reneopharma.com 
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
